IceCure's ProSense™ Gains Traction in Brazil After FDA Breast Cancer Nod
Event summary
- IceCure's ProSense™ system gaining commercial adoption in Brazil following FDA clearance for early-stage breast cancer.
- 750-patient SIX trial underway in Brazil, led by Dr. Vanessa Sanvido at HCor Hospital.
- Dr. Toulsie Ramtohul of Institut Curie invited to Brazilian hospitals and SOBRICE Onco 2026 conference to share clinical expertise.
- ProSense™ procedures already performed for breast, lung, kidney cancer, and musculoskeletal tumors in Brazil.
The big picture
IceCure's expansion in Brazil reflects a broader trend toward minimally invasive cancer treatments, particularly as regulatory approvals open new markets. The company's focus on cryoablation aligns with growing demand for outpatient procedures that reduce recovery times and improve patient outcomes. Success in Brazil could position IceCure as a key player in the $12B global interventional oncology market.
What we're watching
- Regulatory Tailwinds
- Whether FDA clearance will accelerate ProSense™ adoption in other Latin American markets.
- Clinical Validation
- The pace at which the SIX and CRYODESC trials generate data to support broader commercial use.
- Competitive Positioning
- How IceCure differentiates ProSense™ against surgical alternatives in interventional oncology.